Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Digestive Diseases and Sciences (Impact Factor: 2.55). 02/2011; 56(5):1509-15. DOI: 10.1007/s10620-011-1604-3
Source: PubMed

ABSTRACT Response to current therapy of hepatitis C virus (HCV) is suboptimal. Direct-acting antiviral therapies (DAA) are expected to improve treatment outcomes. Additional treatments for HCV will invariably make therapeutic choices and patient management more complex. We hypothesize that current perceptions regarding the complexity of DAA therapy will influence attitudes towards future use by practitioners who are currently treating HCV.
An Internet-based survey was sent to 10,082 AASLD and AGA members to determine if they treat HCV infection, their knowledge of DAA therapies, attitudes towards current and future HCV treatments, and if they participated in clinical trials using DAA agents.
Out of a total of 1,757 individuals responding to the survey, 75% treat HCV; 79% were MDs, 67% were Gastroenterologists, and 24% were Hepatologists. Of the respondents, 77% indicated they were "very aware" or "aware" of DAA therapies, 20% participated in clinical trials, and 3% had minimal knowledge of DAA agents. Comparing treatment "today" versus in the future when DAAs were available, 85 vs. 81% would treat (p = 0.0054), 6 vs. 10% would refer to an "HCV expert" (p = 0.016), and 1% would refer to an ID specialist. Of respondents with "minimal knowledge" of DAA, 52% stated that they would use them in the future.
Although the majority of respondents appear ready to utilize DAA agents in the future, referrals to "hepatitis C experts" will increase. More than half of respondents with "minimal knowledge" of DAA therapies also appear to be willing to utilize these compounds, raising concerns regarding their inappropriate use. Broad education of healthcare providers to prevent inappropriate use of these agents will be critical.

Download full-text


Available from: Paul J Gaglio, Jun 25, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective. Pharmacologic therapy (PT) for patients with esophageal variceal hemorrhage (EVH) may improve outcomes. The aim of this article is to assess the current and potential future use of PT in cirrhotic patients with EVH. Material and methods. We validated a 13-question survey about PT and physician preferences for specific therapies in cirrhotics with EVH; 2349 randomly selected Gastroenterology and Hepatology physicians worldwide were surveyed. The survey addressed institutional location, octreotide or terlipressin use and preference, PT prior to endoscopy, and future plans for terlipressin use, if not already instituted. Results. Of those surveyed, 337 (14%) email addresses were nonfunctioning. Of the remaining 2012 surveyed, 371 (18%) responses were collected. Nearly two-thirds of physicians preferred to use PT prior to endoscopic intervention (p < 0.001). Nearly 70% of respondents only had octreotide available, while 6% had only terlipressin. Of the 24% having both octreotide and terlipressin available, 55% preferred terlipressin compared to 38% who preferred octreotide (p < 0.001). Of those physicians currently not using terlipressin because of its unavailability, 93% would be willing to use it if it were readily available. Conclusions. Of physicians with both terlipressin and octreotide available for treatment of EVH in cirrhotics, most prefer terlipressin, even if currently unavailable.
    Scandinavian Journal of Gastroenterology 11/2013; 49(2). DOI:10.3109/00365521.2013.850736 · 2.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV should continue to be used because of side effects of new drugs such as anemia. Our Japanese experiences should provide new information for the treatment of chronic hepatitis C.
    JNMA; journal of the Nepal Medical Association 01/2011; 51(181):41-8. · 0.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infection with hepatitis C virus (HCV) is a serious public health problem worldwide. In clinical studies, weight loss has been reported in 11% to 29% of patients treated with pegylated interferon-α-2a/2b. Few reports have tried to explain such a weight loss. The aim of this study was to evaluate nutritional status, body composition, and resting energy expenditure (REE) in patients with chronic hepatitis C before and during treatment with pegylated interferon and ribavirin. This was a prospective study with the evaluation of patients with hepatitis C virus before and after 12 wk of treatment with pegylated interferon and ribavirin. The evaluation consisted of anthropometry (weight, height, body mass index, and waist circumference), and body composition was determined by bioelectrical impedance analysis. The REE of each individual was obtained by indirect calorimetry. To compare the two phases of treatment, the Wilcoxon test was used. The significance level was 5%. Subjects had significant weight loss during treatment with a consequent decrease in body mass index. This weight decrease was accompanied by a significant decrease in body fat and no decrease in fat-free mass. There was a significant decrease in energy intake as assessed by 24-h recall. However, there was no change in REE and in REE corrected for fat-free mass. Our study of patients with hepatitis C treatment showed that these patients had significant weight loss and this was not associated with changes in energy expenditure. However, we observed a significant decrease in energy intake, pointing to a possible need for intervention measures to decrease the damage.
    Nutrition 12/2011; 28(6):630-4. DOI:10.1016/j.nut.2011.08.010 · 3.05 Impact Factor